ARTICLE | Clinical News
Humira adalimumab: Phase III; marketed for rheumatoid arthritis (RA)
October 13, 2003 7:00 AM UTC
ABT started a double-blind, placebo-controlled U.S. Phase III study of Humira in an undisclosed number of patients with psoriatic arthritis that have had inadequate response to disease-modifying anti-...